Crossmark

Identification and drug-induced reversion of molecular signatures of Alzheimer’s disease onset and progression in AppNL-G-F, AppNL-F, and 3xTg-AD mouse models

Crossref DOI link: https://doi.org/10.1186/s13073-021-00983-y

Published Online: 2021-10-26

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pauls, Eduardo

Bayod, Sergi

Mateo, Lídia

Alcalde, Víctor

Juan-Blanco, Teresa

Sánchez-Soto, Marta

Saido, Takaomi C.

Saito, Takashi

Berrenguer-Llergo, Antoni

Attolini, Camille Stephan-Otto

Gay, Marina

de Oliveira, Eliandre

Duran-Frigola, Miquel

Aloy, Patrick http://orcid.org/0000-0002-3557-0236
Funding

Funding for this research was provided by:

H2020 European Research Council (614944)

Ministerio de Ciencia, Innovación y Universidades (BIO2016-77038-R)

Departament d'Innovació, Universitats i Empresa, Generalitat de Catalunya (001-P-001682, 001-P-001647)
License Information

Text and Data Mining valid from 2021-10-26

Version of Record valid from 2021-10-26
More Information

Article History

Received: 16 April 2021

Accepted: 29 September 2021

First Online: 26 October 2021

Declarations

:

: All the animal experiments have been performed following the Ethics Committee rules of the Institute following the current European legislation (Council Directive 86/609/EEC; Law 5/1995/GC; Order 214/1997/GC; Law 1201/2005/SG) and all the protocols have been authorized by the Direcció General del Medi Ambient i Biodiversitat (Calatalan Government) n<sup>o</sup> DAM:5880 (authorization numbers 8478, 8527 and 10382).

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below